<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01270087</url>
  </required_header>
  <id_info>
    <org_study_id>REUMAUMAS 2005-1</org_study_id>
    <secondary_id>2005-000129-47</secondary_id>
    <nct_id>NCT01270087</nct_id>
  </id_info>
  <brief_title>The Effect of Adalimumab (Humira) on Vascular Abnormalities in Rheumatoid Arthritis. A Pilot Study.</brief_title>
  <official_title>The Effect of Adalimumab (Humira) on Vascular Abnormalities in Rheumatoid Arthritis. A Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Swedish Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Swedish Rheumatism Ass</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Crafoord Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Skane University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether anti-inflammatory treatment with adalimumab
      (Humira) reduces endothelial activation in blood vessels in patients with active rheumatoid
      arthritis. Markers of endothelial activation are assessed in muscle tissue before treatment
      and after 3 months, and related to other biomarkers and clinical outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial expression of HLA-DQ in muscle biopsies</measure>
    <time_frame>3 months</time_frame>
    <description>Vascular tissue area stained for HLA-DQ by immunohistochemistry, quantified by computer assisted image analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endothelial expression of interleukin-1 alpha in muscle biopsies</measure>
    <time_frame>3 months</time_frame>
    <description>Vascular tissue area stained for interleukin-1 alpha by immunohistochemistry, quantified by computer assisted image analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carotid artery intima-media thickness</measure>
    <time_frame>3 months</time_frame>
    <description>Thickness of the intima and media of the common carotid artery, measured by ultrasound. Mean of two measures of the right and left common carotid artery.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Adalimumab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>40 mg IV every 14 days</description>
    <arm_group_label>Adalimumab</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of rheumatoid arthritis

          -  Fulfillment of the American College of Rheumatology 1987 criteria for rheumatoid
             arthritis

          -  Active disease despite treatment with at least one disease modifying anti-rheumatic
             drug

          -  Treatment with adalimumab indicated according to the the patient's rheumatologist

          -  At least six swollen joints in 28-joint index

          -  CRP &gt; 8 mg / L within the last three months

        Exclusion Criteria:

          -  Treatment with anti-TNF drugs in the last three months

          -  Treatment with intravenous corticosteroids within fourteen days

          -  Ongoing treatment with oral high-dose corticosteroids (equivalent to ≥ 20 mg of
             prednisolon daily) or completed such treatment less than fifteen days before inclusion

          -  Severe bleeding disorder

          -  Extensive or refractory leg ulcers

          -  Severe peripheral vascular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl Turesson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Rheumatology, Skåne University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Rheumatology, Skåne University Hospital</name>
      <address>
        <city>Malmö</city>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2011</study_first_submitted>
  <study_first_submitted_qc>January 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2011</study_first_posted>
  <last_update_submitted>January 4, 2011</last_update_submitted>
  <last_update_submitted_qc>January 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Carl Turesson, Associate Professor</name_title>
    <organization>Department of Rheumatology, Skåne University Hospital</organization>
  </responsible_party>
  <keyword>Rheumatoid arthritis, cardiovascular disease, adalimumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

